Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Nano Regulatory News (ONT)

Share Price Information for Oxford Nano (ONT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 108.80
Bid: 108.10
Ask: 108.70
Change: 6.10 (5.94%)
Spread: 0.60 (0.555%)
Open: 105.00
High: 109.20
Low: 102.70
Prev. Close: 102.70
ONT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of Annual Report and Notice of AGM

12 Apr 2022 07:00

RNS Number : 0372I
Oxford Nanopore Technologies plc
12 April 2022
 

12 April 2022

Oxford Nanopore Technologies plc

(the "Company")

Publication of 2021 Annual Report and Notice of Annual General Meeting

 

Oxford Nanopore Technologies plc, the company behind a new generation of nanopore-based sequencing technology, today announces that it has published its Annual Report and Accounts for the year ended 31 December 2021 and its Notice of Annual General Meeting 2022.

In compliance with Listing Rule 9.6.3, the following documents have today been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism:

· Annual Report and Accounts for the year ended 31 December 2021 ("2021 ARA"); and

· Notice of 2022 Annual General Meeting ("2022 AGM Notice").

Printed copies of these documents together with the Form of Proxy for use in connection with the 2022 Annual General Meeting have been posted to shareholders who have requested hard copies. Electronic copies of the 2021 ARA and 2022 AGM Notice are available on the Investor Relations section of the Company's website at https://nanoporetech.com/about-us/investors.

The 2022 Annual General Meeting will be held at the Company's offices at Gosling Building, Edmund Halley Road, Oxford Science Park, Oxford, OX4 4DQ at 11.00am on Thursday 23 June 2022.

At the time of publication of this Notice, there are no UK government restrictions that prevent the Company from holding its AGM in person. If the Covid-19 guidance changes at any point prior to the AGM, such that shareholders are unable to attend in person, the Company will update shareholders through an announcement to the London Stock Exchange and on the Company's website at https://nanoporetech.com/about-us/investors. Shareholders who plan to attend the AGM in person should take a lateral flow test and ensure a negative result before entering the Company's offices. Shareholders should not attend if they are displaying any symptoms of Covid-19.

Shareholders are strongly encouraged to ensure that their votes are counted at the 2022 Annual General Meeting by appointing the chair of the 2022 Annual General Meeting as their proxy in line with the procedures set out in the 2022 AGM Notice.

[ENDS]

For further information please contact:

Oxford Nanopore Technologies plc

Hannah Coote, Company Secretary

cosec@nanoporetech.com 

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 120 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture. 

 

Oxford Nanopore devices sequence DNA and RNA directly and sequence short to ultra-long fragments of DNA, for a truly comprehensive picture of the genome. Data is streamed in real-time and can enable rapid insights. The technology is fully scalable - from pocket-sized to ultra-high throughput devices. 

 

For more information please visit: www.nanoporetech.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOADBGDSLGBDGDB
Date   Source Headline
13th May 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
1st May 20245:00 pmRNSIssue of Equity and Total Voting Rights
1st May 20247:00 amRNSDirector/PDMR Shareholding
30th Apr 20247:00 amRNSPublication of Annual Report and Notice of AGM
12th Apr 20241:00 pmRNSStudy unlocks insights into disease and longevity
12th Apr 202412:00 pmRNSLTIP and DBP; Director/PDMR Notification
11th Apr 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
8th Apr 20244:00 pmRNSBlock Listing Interim Review
2nd Apr 20242:00 pmRNSIssue of Equity and Total Voting Rights
28th Mar 20245:55 pmRNSHolding(s) in Company
12th Mar 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
12th Mar 20247:00 amRNSOxford Nanopore to Present at Barclays Conference
8th Mar 202412:00 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirector/PDMR Shareholding
6th Mar 20247:00 amRNSFY23 Preliminary Results
1st Mar 20242:00 pmRNSIssue of Equity and Total Voting Rights
29th Feb 20246:00 pmRNSDirectorate Change
13th Feb 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
2nd Feb 20244:30 pmRNSHolding(s) in Company
1st Feb 202412:00 pmRNSIssue of Equity and Total Voting Rights
22nd Jan 20247:00 amRNSExpansion of leadership team
11th Jan 20245:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
11th Jan 20245:30 pmRNSEmployee Stock Purchase Plan - PDMR Notification
9th Jan 20247:00 amRNSFY23 trading update
3rd Jan 20247:00 amRNSPresentation at 42nd Annual J.P. Morgan Conference
19th Dec 20232:00 pmRNSAppointment of Two Non-Executive Directors
12th Dec 20235:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
7th Dec 20234:30 pmRNSNanopore Community Meeting Technology Update
1st Dec 20235:00 pmRNSIssue of Equity and Total Voting Rights
30th Nov 20237:00 amRNSNational Australian rare disease programme
13th Nov 20235:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
13th Nov 202312:00 pmRNSParticipation in upcoming investor conferences
7th Nov 20238:30 amRNSAdmission to Trading on the London Stock Exchange
6th Nov 20237:00 amRNSIssue of Equity
1st Nov 20234:00 pmRNSIssue of Equity and Total Voting Rights
31st Oct 20237:00 amRNSApple showcases Oxford Nanopore in M3 launch
26th Oct 20236:10 pmRNSHolding(s) in Company
24th Oct 202312:30 pmRNSHolding(s) in Company
23rd Oct 20238:30 amRNSAdmission to Trading on the London Stock Exchange
23rd Oct 20238:30 amRNSIssue of Equity and Total Voting Rights
19th Oct 20237:00 amRNSCapital Markets Day - ONT expands into clinical
19th Oct 20237:00 amRNSbioMérieux makes investment in Oxford Nanopore
19th Oct 20237:00 amRNSMayo Clinic and Oxford Nanopore collaboration
11th Oct 20233:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
6th Oct 20233:00 pmRNSBlock Listing Interim Review
2nd Oct 20234:00 pmRNSIssue of Equity and Total Voting Rights
27th Sep 20235:00 pmRNSDirector Declaration
12th Sep 20233:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
12th Sep 20237:00 amRNSPresentation at the Morgan Stanley Conference
6th Sep 20237:00 amRNSInterim results for the 6 months ended 30 June 23

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.